Lion Considers Withdrawing from Nasdaq; Reports Sharp Drop in Revenues for Q4 of FY03/04 | GenomeWeb

NEW YORK, June 23 (GenomeWeb News) - Lion Bioscience considers withdrawing from Nasdaq after reporting sharply dropped revenues and narrowed losses for the fourth quarter of its fiscal year 2003/2004 today, which ended March 31.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.